Cargando…

Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening

Over the years, numerous groups have employed human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) as a superb human-compatible model for investigating the function and dysfunction of cardiomyocytes, drug screening and toxicity, disease modeling and for the development of novel drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ovics, Paz, Regev, Danielle, Baskin, Polina, Davidor, Mor, Shemer, Yuval, Neeman, Shunit, Ben-Haim, Yael, Binah, Ofer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582587/ https://www.ncbi.nlm.nih.gov/pubmed/33023024 http://dx.doi.org/10.3390/ijms21197320

Ejemplares similares

Investigating LMNA-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Shemer, Yuval, et al.
Publicado: (2021)

Electrophysiological abnormalities in induced pluripotent stem cell‐derived cardiomyocytes generated from Duchenne muscular dystrophy patients
por: Eisen, Binyamin, et al.
Publicado: (2019)

Depressed β‐adrenergic inotropic responsiveness and intracellular calcium handling abnormalities in Duchenne Muscular Dystrophy patients’ induced pluripotent stem cell–derived cardiomyocytes
por: Mekies, Lucy N., et al.
Publicado: (2021)

Modeling Duchenne Muscular Dystrophy Cardiomyopathy with Patients’ Induced Pluripotent Stem-Cell-Derived Cardiomyocytes
por: Eisen, Binyamin, et al.
Publicado: (2023)

Bioenergetic and Metabolic Impairments in Induced Pluripotent Stem Cell-Derived Cardiomyocytes Generated from Duchenne Muscular Dystrophy Patients
por: Willi, Lubna, et al.
Publicado: (2022)

Investigating the cardiac pathology of SCO2‐mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell–derived cardiomyocytes
por: Hallas, Tova, et al.
Publicado: (2017)

Editorial: Acquired and Inherited Cardiac Arrhythmias
por: Ben-Haim, Yael, et al.
Publicado: (2022)

Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes
por: Novak, Atara, et al.
Publicado: (2012)

Functional abnormalities in induced Pluripotent Stem Cell-derived cardiomyocytes generated from titin-mutated patients with dilated cardiomyopathy
por: Schick, Revital, et al.
Publicado: (2018)

Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure
por: Gherghiceanu, Mihaela, et al.
Publicado: (2011)

cAMP-PKA signaling modulates the automaticity of human iPSC-derived cardiomyocytes
por: Mazgaoker, Savyon, et al.
Publicado: (2022)

A Method Sustaining the Bioelectric, Biophysical, and Bioenergetic Function of Cultured Rabbit Atrial Cells
por: Kirschner Peretz, Noa, et al.
Publicado: (2017)

Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells
por: Germanguz, Igal, et al.
Publicado: (2011)

Induced Pluripotent Stem Cell–Derived Cardiomyocytes Provide In Vivo Biological Pacemaker Function
por: Chauveau, Samuel, et al.
Publicado: (2017)

Drug screening platform using human induced pluripotent stem cell‐derived atrial cardiomyocytes and optical mapping
por: Gunawan, Marvin G., et al.
Publicado: (2020)

Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening
por: Sharma, Arun, et al.
Publicado: (2013)

Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity
por: Schwach, Verena, et al.
Publicado: (2020)

Cardiomyocytes generated from CPVT(D307H) patients are arrhythmogenic in response to β-adrenergic stimulation
por: Novak, Atara, et al.
Publicado: (2012)

SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients
por: Jimenez-Vazquez, Eric N, et al.
Publicado: (2022)

Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity
por: Wang, Ping-Hsien, et al.
Publicado: (2022)

Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes
por: Kuusela, Jukka, et al.
Publicado: (2016)

Concise Review: Measuring Physiological Responses of Human Pluripotent Stem Cell Derived Cardiomyocytes to Drugs and Disease
por: van Meer, Berend J., et al.
Publicado: (2016)

Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease
por: Lin, Ziliang Carter, et al.
Publicado: (2017)

Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?
por: Christ, Torsten, et al.
Publicado: (2021)

A Bioprinted Heart-on-a-Chip with Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Evaluation
por: Faulkner-Jones, Alan, et al.
Publicado: (2022)

Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes
por: Chaudhari, Umesh, et al.
Publicado: (2017)

Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation
por: Tang, Xiaoli, et al.
Publicado: (2022)

Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: El-Battrawy, Ibrahim, et al.
Publicado: (2016)

Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells
por: Nemade, Harshal, et al.
Publicado: (2018)

Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Duncan, Gary, et al.
Publicado: (2017)

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment
por: Blinova, Ksenia, et al.
Publicado: (2018)

Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Rubi, Lena, et al.
Publicado: (2016)

Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs
por: Sachinidis, Agapios
Publicado: (2020)

Single-Cell Mechanical Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Testing and Pathophysiological Studies
por: Ballan, Nimer, et al.
Publicado: (2020)

Effects of Cryopreservation on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Assessing Drug Safety Response Profiles
por: Zhang, Joe Z., et al.
Publicado: (2020)

Reply to ‘Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?’
por: Shiti, Assad, et al.
Publicado: (2021)

Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells
por: Holmgren, Gustav, et al.
Publicado: (2015)

High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes
por: Grimm, Fabian Alexander, et al.
Publicado: (2015)

MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes
por: Chaudhari, Umesh, et al.
Publicado: (2016)

Supervised Machine Learning for Classification of the Electrophysiological Effects of Chronotropic Drugs on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Heylman, Christopher, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tr94h0nl30akeobdr1agqioo5e